Innovative vaccines for a healthier world
Interview with CEO Bent Frandsen
Next Event
-
Mon18Mar2024Wed20Mar2024Barcelona, Spain
BIO-EUROPE Spring
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information is available at BIO-Europe’s website.
Attendees | BIO-Europe Spring (informaconnect.com)
Latest News
ExpreS2ion to present in investor and R&D events in March
Hørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
Read moreExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine
Hørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces that AdaptVac ApS (“AdaptVac”) has received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s…
Read moreExpreS2ion announces financial results for the fourth quarter and full-year 2023
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.
Read more